跳至主要内容
临床试验/NCT02551458
NCT02551458终止2 期

SYSTEMATIC SURGERY VERSUS SURVEILLANCE AND RESCUE SURGERY IN OPERABLE CANCER OF THE OESOPHAGUS WITH A COMPLETE CLINICAL RESPONSE TO RADIOCHEMOTHERAPY

Centre Hospitalier Universitaire Dijon18 个研究点 分布在 1 个国家目标入组 188 人开始时间: 2016年3月14日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
终止
入组人数
188
试验地点
18
主要终点
Disease-free survival

研究概览

简要总结

Step 1: Inclusion of eligible patients to carry out a translational search for prognostic and predictive markers of Complete Clinical Response and Pathologic Complete Response (using blood samples and diagnostic biopsies) and to collect data on radiochemotherapy and its toxicity.

The trial will evaluate strategies after neoadjuvant treatment and not RCT protocols. The RCT will thus be chosen by the investigator from published effective schemes in a pre-operative setting or in patients not undergoing surgery.

Evaluation of the response 5 to 6 weeks after the RCT.

Step 2: Randomisation in patients with a complete clinical response:

Arm A: Systematic surgery Arm B: Surveillance and rescue surgery in cases with resectable loco-regional recurrence

Patients not eligible for randomisation will have the possibility to participate in a specific study (information can be obtained from the SAKK group (Switzerland Group Clinical Research on Cancer)).

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Epidermoid carcinoma (EC) or adenocarcinoma of the thoracic oesophagus or adenocarcinoma of the oesogastric junction (Siewert type I or II) proven histologically
  • •Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 after a full investigation
  • •Patient considered operable with a curative intent and scheduled to undergo first-line radiochemotherapy in a multidisciplinary meeting
  • •Age ≥ 18 years < 75 years
  • •Patient with national health insurance cover and who has provided written informed consent for the clinical and biological studies.

排除标准

  • •Cancer of the cervical oesophagus (15 to 19 cm from the dental arches)
  • •Weight loss > 15% at the recruitment with no improvement after nutritional support
  • •Serious comorbidity threatening survival in the short term
  • •Contra-indication for radiochemotherapy
  • •Other uncured malignant disease in the 5 previous years (except for in situ cervical carcinoma and treated non-melanotic skin cancers)
  • •Absence of effective contraception in patients (men or women) able to procreate, pregnant or breast-feeding women
  • •Impossibility to follow the trial
  • •Legal disqualification (patients in custody or under guardianship)

研究组 & 干预措施

Arm A: Systematic surgery

Experimental

干预措施: Systematic surgery (Other)

Arm B: Surveillance and rescue surgery in cases of resectable

Experimental

干预措施: Surveillance and rescue surgery in cases of resectable loco-regional recurrence (Other)

结局指标

主要结局

Disease-free survival

时间窗: Up to 5 years

Proportion of surviving patients

时间窗: 1 year after randomisation

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验